Relay Therapeutics (RLAY) Competitors $2.86 -0.19 (-6.23%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$2.86 0.00 (-0.17%) As of 05/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RLAY vs. NAMS, AAPG, KYMR, BHVN, IBRX, HRMY, TWST, BLTE, KNSA, and ARWRShould you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include NewAmsterdam Pharma (NAMS), Ascentage Pharma Group International (AAPG), Kymera Therapeutics (KYMR), Biohaven (BHVN), ImmunityBio (IBRX), Harmony Biosciences (HRMY), Twist Bioscience (TWST), Belite Bio (BLTE), Kiniksa Pharmaceuticals (KNSA), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Relay Therapeutics vs. NewAmsterdam Pharma Ascentage Pharma Group International Kymera Therapeutics Biohaven ImmunityBio Harmony Biosciences Twist Bioscience Belite Bio Kiniksa Pharmaceuticals Arrowhead Pharmaceuticals Relay Therapeutics (NASDAQ:RLAY) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, community ranking, risk, earnings, media sentiment, institutional ownership and dividends. Is RLAY or NAMS more profitable? NewAmsterdam Pharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% NewAmsterdam Pharma N/A N/A N/A Does the MarketBeat Community prefer RLAY or NAMS? Relay Therapeutics received 35 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 96.55% of users gave NewAmsterdam Pharma an outperform vote while only 70.00% of users gave Relay Therapeutics an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes6370.00% Underperform Votes2730.00% NewAmsterdam PharmaOutperform Votes2896.55% Underperform Votes13.45% Which has higher valuation and earnings, RLAY or NAMS? NewAmsterdam Pharma has higher revenue and earnings than Relay Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$7.68M63.85-$341.97M-$2.23-1.28NewAmsterdam Pharma$47.14M43.12-$176.94M-$1.88-9.85 Do analysts prefer RLAY or NAMS? Relay Therapeutics currently has a consensus target price of $17.67, suggesting a potential upside of 517.72%. NewAmsterdam Pharma has a consensus target price of $43.00, suggesting a potential upside of 132.31%. Given Relay Therapeutics' higher possible upside, research analysts clearly believe Relay Therapeutics is more favorable than NewAmsterdam Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83NewAmsterdam Pharma 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor RLAY or NAMS? In the previous week, Relay Therapeutics had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 9 mentions for Relay Therapeutics and 7 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.37 beat Relay Therapeutics' score of 1.25 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, RLAY or NAMS? Relay Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Do institutionals and insiders believe in RLAY or NAMS? 97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 4.9% of Relay Therapeutics shares are owned by company insiders. Comparatively, 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. SummaryNewAmsterdam Pharma beats Relay Therapeutics on 9 of the 17 factors compared between the two stocks. Get Relay Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLAY vs. The Competition Export to ExcelMetricRelay TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$490.33M$2.93B$5.38B$8.39BDividend YieldN/A1.71%5.21%4.10%P/E Ratio-1.1030.5026.8019.71Price / Sales63.85400.15389.55117.28Price / CashN/A168.6838.2534.62Price / Book0.483.286.804.50Net Income-$341.97M-$72.17M$3.23B$248.18M7 Day Performance2.51%2.96%1.53%0.23%1 Month Performance-2.39%3.25%10.05%12.39%1 Year Performance-62.02%-28.29%16.75%7.07% Relay Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLAYRelay Therapeutics3.1707 of 5 stars$2.86-6.2%$17.67+517.7%-62.2%$490.33M$7.68M-1.10330Positive NewsGap DownNAMSNewAmsterdam Pharma2.6636 of 5 stars$19.22+4.6%$43.00+123.7%-5.0%$2.11B$45.56M-10.224Gap UpAAPGAscentage Pharma Group InternationalN/A$24.20-0.5%N/AN/A$2.11B$980.65M0.00600Positive NewsKYMRKymera Therapeutics2.7114 of 5 stars$32.17+7.0%$55.53+72.6%-14.7%$2.09B$47.07M-13.75170Analyst ForecastGap DownBHVNBiohaven3.4861 of 5 stars$20.47+1.1%$62.54+205.5%-59.4%$2.09BN/A-2.19239Analyst DowngradeGap DownIBRXImmunityBio1.8548 of 5 stars$2.36+14.0%$12.19+416.4%-61.1%$2.08B$14.75M-2.57590Analyst UpgradeHigh Trading VolumeHRMYHarmony Biosciences4.7872 of 5 stars$35.65+4.7%$52.33+46.8%+16.4%$2.05B$744.85M16.90200Positive NewsTWSTTwist Bioscience4.2968 of 5 stars$32.95+6.9%$50.40+53.0%-35.4%$1.97B$347.68M-9.75990Positive NewsBLTEBelite Bio2.0486 of 5 stars$61.99+1.5%$96.67+55.9%+48.2%$1.97BN/A-55.8510News CoverageAnalyst RevisionGap UpKNSAKiniksa Pharmaceuticals2.9552 of 5 stars$26.84+3.1%$38.80+44.6%+34.8%$1.95B$481.17M-191.70220Positive NewsInsider TradeARWRArrowhead Pharmaceuticals3.5161 of 5 stars$13.97+7.2%$41.44+196.7%-38.8%$1.92B$2.50M-2.70400Positive NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies NAMS Alternatives AAPG Alternatives KYMR Alternatives BHVN Alternatives IBRX Alternatives HRMY Alternatives TWST Alternatives BLTE Alternatives KNSA Alternatives ARWR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLAY) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe DOJ Just Said Your Money Isn’t YoursWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relay Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relay Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLAY Stock Free RLAY Stock Alerts